Cerebral Gliosis, Positron Emission Tomography
Conditions
Brief summary
In this clinical study, we proposed to perform \[18F\]BF3-BPA PET imaging in subjects with gliomas, to observe the binding ability and non-specific binding of the tracer to glioma lesions in vivo, and at the same time to evaluate the effectiveness of \[18F\]BF3-BPA in the diagnosis and differential diagnosis of glioma, and to evaluate the tolerability and safety of the tracer and the imaging method. The efficacy of \[18F\]BF3-BPA in the diagnosis and differential diagnosis of gliomas will be evaluated, as well as the tolerability and safety of this tracer and imaging method. This study will provide a new method for in vivo imaging of gliomas and provide a clear and intuitive imaging basis for clinical diagnosis, differential diagnosis and treatment.
Interventions
RADIATION[18F]BF3-BPA Injection for PET Imaging
Two dosing dose groups were designed, 5±1 mCi or 9±1 mCi, with 20 subjects in each dose group, and the high dose group study was conducted after enrollment in the low dose group was completed.
Sponsors
Huashan Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* 1\. Patients with suspicious brain gliomas: * Patients diagnosed by the investigator, based on symptoms, course of disease, and MRI of the head, as having a suspected high- or low-grade brain glioma, scheduled for brain tumor resection, and with no contraindications to surgery; * No prior and/or current surgery, radiotherapy, or puncture biopsy (other than treatment for symptomatic relief) for brain tumors; * No other primary malignant tumor. 2. age ≥ 18 years; 3. Eastern Cooperative Oncology Group (ECOG) 0-2; 4. adequate organ function: * Platelet count \>100 x 109/L; * Urea/urea nitrogen and serum creatinine \<1.5 times upper limit of normal (ULN); * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2.5 times ULN. 5\. Subjects should be fully informed of the content, process and possible risks of the test and voluntarily sign an informed consent form.
Exclusion criteria
* Subjects meeting any of the following criteria will be excluded from the study: 1. Severe allergic reaction to any of the drugs or their components in this trial; 2. Those who cannot tolerate or are contraindicated to undergo MRI and PET; 3. Those who cannot accept or tolerate blood sample collection; 4. Those who are unable to use effective contraception from the date of signing the informed consent to 3 months after the administration of the drug; 5. pregnant or lactating women or those with positive blood pregnancy test results; 6. Those who have participated in other interventional clinical trials prior to the date of informed consent and are within 5 half-lives of the trial drug, or are participating in other interventional clinical trials;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete PET imaging | 90mins from time of injection | To evaluate the biodistribution characteristics (SUVmax, SUVmean) of PET imaging with different doses of \[18F\]BF3-BPA in brain tumor/normal brain tissues of patients with suspected gliomas, and to obtain the optimal imaging time and optimal dose of \[18F\]BF3-BPA PET imaging in patients with suspected gliomas. |
Countries
China
Contacts
Primary ContactYihui Guan, MD
Outcome results
None listed